tiprankstipranks
Supernus Pharmaceuticals (GB:0LB2)
LSE:0LB2
UK Market

Supernus Pharmaceuticals Stock Analysis & Ratings

GB:0LB2 Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$27.41
VolumeN/A
Average Volume (3M)60.00
Market Cap$1.46B
P/E RatioN/A
Beta1.17
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0LB2 FAQ

What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Supernus Pharmaceuticals’s market cap?
    Supernus Pharmaceuticals’s market cap is $1.46B.
      What is Supernus Pharmaceuticals’s price target?
      The average price target for Supernus Pharmaceuticals is $38.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $44.00 ,the lowest forecast is $33.00. The average price target represents 40.46% Increase from the current price of $27.41.
        What do analysts say about Supernus Pharmaceuticals?
        Supernus Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Supernus Pharmaceuticals’s upcoming earnings report date?
          Supernus Pharmaceuticals’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
            How were Supernus Pharmaceuticals’s earnings last quarter?
            Supernus Pharmaceuticals released its earnings results on May 09, 2022. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.318 by $0.112.
              Is Supernus Pharmaceuticals overvalued?
              According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
                Does Supernus Pharmaceuticals pay dividends?
                Supernus Pharmaceuticals does not currently pay dividends.
                What is Supernus Pharmaceuticals’s EPS estimate?
                Supernus Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Supernus Pharmaceuticals have?
                Supernus Pharmaceuticals has 53,410,000 shares outstanding.
                  What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
                  Supernus Pharmaceuticals reported an EPS of $0.43 in its last earnings report, beating expectations of $0.318. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
                    Among the largest hedge funds holding Supernus Pharmaceuticals’s share is Bruce & Co., Inc.. It holds Supernus Pharmaceuticals’s shares valued at 7M.

                      ---

                      Supernus Pharmaceuticals Stock Analysis

                      The Supernus Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Supernus Pharmaceuticals

                      Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Marinus
                      Catalent
                      Ovid Therapeutics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis